Lineage Cell Therapeutics, previously BioTime, announced the effective change of its corporate name and formal launch of its new corporate brand. In connection with the launch, the company’s NYSE American ticker symbol has changed to “LCTX” and will be effective at the open of the market today. The new website for Lineage Cell Therapeutics will be www.lineagecell.com.
Lineage’s clinical assets include OpRegen, a retinal pigment epithelium transplant therapy in phase 1/2a development for the treatment of dry age-related macular degeneration.
“It has been less than one year since I joined the company and I’m excited that we have largely completed the strategic and multi-faceted plan to simplify our business structure and re-position ourselves as one of the most promising and focused cell therapy companies,” Brian M. Culley, Chief Executive Officer of Lineage Cell Therapeutics, said in a company news release. “We look forward to inviting stakeholders to rediscover what sets us apart from other companies and to join us as we embark on the next step of this exciting journey. Control the lineage of cells; don’t leave it up to fate.”